Evaluation of the risk of cardiovascular events with clarithromycin using both propensity score and self-controlled study designs

British Journal of Clinical Pharmacology

Volumn , Issue , 2016, Pages 512-521

  Root, Adrian A ^a   Wong, Angel Y S ^b   Ghebremichael Weldeselassie, Yonas ^c   Smeeth, Liam ^a   Bhaskaran, Krishnan ^a   Evans, Stephen J W ^a   Brauer, Ruth ^a   Wong, Ian Chi Kei ^d   Navaratnam, Vidya ^a   Douglas, Ian ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c OPEN UNIVERSITY   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

adverse drug reaction; cardiovascular disease; clarithromycin; pharmacoepidemiology

Indexed keywords

CLARITHROMYCIN;

ADOLESCENT; ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHILD; COHORT ANALYSIS; DRUG EXPOSURE; EVALUATION STUDY; FEMALE; HEART ARRHYTHMIA; HEART INFARCTION; HELICOBACTER INFECTION; HUMAN; INCIDENCE; INFANT; MALE; NEWBORN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPENSITY SCORE; UNITED KINGDOM;

EID: 84978764158     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12983     Document Type: Article

References (13)

1. Jespersen CM. Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial. BMJ 2006; 332: 22–7.
2. Schembri S, Williamson PA, Short PM, Singanayagam A, Akram A, Taylor J, et al. Cardiovascular events after clarithromycin use in lower respiratory tract infections: analysis of two prospective cohort studies. BMJ 2013; 346: –f1235.
3. Wong AYS, Root A, Douglas IJ, Chui CSL, Chan EW, Ghebremichael-Weldeselassie Y, et al. Cardiovascular outcomes associated with use of clarithromycin: population based study. BMJ 2016; 352: h6926.
4. Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ. Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol 2010; 69: 4–14.
5. Herrett E, Shah AD, Boggon R, Denaxas S, Smeeth L, van Staa T, et al. Completeness and diagnostic validity of recording acute myocardial infarction events in primary care, hospital care, disease registry, and national mortality records: cohort study. BMJ [Internet]. 2013 May 21; 346 Available at: http://www.bmj.com/content/346/bmj.f2350.abstract (last accessed 27 August 2013).
6. Stürmer T, Rothman KJ, Avorn J, Glynn RJ. Treatment effects in the presence of unmeasured confounding: dealing with observations in the tails of the propensity score distribution–a simulation study. Am J Epidemiol 2010; 172: 843–54.
7. Whitaker HJ, Paddy Farrington C, Spiessens B, Musonda P. Tutorial in biostatistics: the self-controlled case series method. Stat Med 2006; 25: 1768–97.
8. Whitaker HJ, Hocine MN, Farrington CP. The methodology of self-controlled case series studies. Stat Methods Med Res 2009; 18: 7–26.
9. Ghebremichael-Weldesselaissie Y, Whitaker HJ, Farrington CP. Spline-based self-controlled case series method. Technical Report. Open Univ Milton Keynes [Internet]. 2015 Feb 15; Available from: http://statistics.open.ac.uk
10. Suissa S. The case-time-control design. Epidemiology 1995; 6: 248–53.
11. Brauer R, Smeeth L, Anaya-Izquierdo K, Timmis A, Denaxas SC, Farrington CP, et al. Antipsychotic drugs and risks of myocardial infarction: a self-controlled case series study. Eur Heart J 2014; 36: 984–92.
12. Farrington CP, Whitaker HJ. Semiparametric analysis of case series data. J R Stat Soc Ser C Appl Stat 2006; 55: 553–94.
13. Svanstrom H, Pasternak B, Hviid A. Use of clarithromycin and roxithromycin and risk of cardiac death: cohort study. BMJ 2014; 349: g4930.